RankingsPricing
  1. US-listed companies
  2. ACURA PHARMACEUTICALS, INC
  3. Financials
  4. Diluted EPS

ACURA PHARMACEUTICALS, INCACUR

Market cap
P/E ratio
SummaryFinancials
Period EndDiluted EPS (USD)YoY (%)
Dec 31, 2021-0-50.00%
Dec 31, 2020-0-71.43%
Dec 31, 2019-0.1-22.22%
Dec 31, 2018-0.2-50.00%
Dec 31, 2017-0.4-41.94%
Dec 31, 2016-0.6+34.78%
Dec 31, 2015-0.5+70.37%
Dec 31, 2014-0.3-6.90%
Dec 31, 2013-0.3+45.00%
Dec 31, 2012-0.2-190.91%
Dec 31, 20110.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)